Results 31 to 40 of about 4,435,862 (297)

Direct Oral Anticoagulants

JACC: Cardiovascular Interventions, 2014
This chapter reviews the new direct oral anticoagulants—thrombin inhibitor and Xa inhibitors. The specific drugs are reviewed as well as the specific indications—prevention and treatment of deep venous thrombosis, stroke prevention in atrial fibrillation, and then acute coronary syndrome.
Levy, Jerrold H., Spyropoulos, Alex C., Samama, Charles M., Douketis, James   +3 more
openaire   +2 more sources

Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants

, 2021
Background: Patient's adherence to oral anticoagulant therapy is essential to prevent and treat thrombotic events. Methods: To assess the patients' adherence Morisky Medication Adherence Scale 8-items was used.
Perra F., Marongiu F., Barcellona D., Cornacchini S., Farci N., Diovaldi M., Moledda V., Mameli A.   +7 more
core   +1 more source

Safety and differences between direct oral anticoagulants and vitamin K antagonists in the risk of post-traumatic intrathoracic bleeding after rib fractures in elderly patients

Emergency Care Journal, 2021
Closed chest traumas are frequent consequences of falls in the elderly. The presence of concomitant oral anticoagulant therapy can increase the risk of post-traumatic bleeding even in cases of trauma with non-severe dynamics. There is limited information
Gianni Turcato, Arian Zaboli, Andrea Tenci, Giorgio Ricci, Massimo Zannoni, Christoph Scheurer, Anton Wieser, Antonio Maccagnani, Antonio Bonora, Norbert Pfeifer   +9 more
doaj   +1 more source

The new, direct, target-specific oral anticoagulants

Journal of Applied Hematology, 2015
In recent years, numerous alternatives to VKAs have been developed, the first competitors to warfarin are the novel oral anticoagulants (NOAC) or better referred to as Direct Oral Anti-Coagulant (DOAC) or Target Specific Oral Anti-coagulant (TSOAC ...
Nevine A Kassim
doaj   +1 more source

Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)

Biomedicines, 2021
The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous anticoagulant therapies.
Claire Dunois
doaj   +1 more source

Direct oral anticoagulants: A new chapter in anticoagulation therapy [PDF]

Arhiv za farmaciju, 2020
Thromboembolic events are the leading cause of morbidity and mortality worldwide. From the second half of the 20th century, vitamin K antagonists (VKAs), warfarin and acenocoumarol, were the only anticoagulants taken orally. The major reform in anticoagulation therapy was made by the advent of direct oral anticoagulants (DOACs), about 10 years ago ...
Radica Stepanović-Petrović, Katarina Nastić   +1 more
openaire   +3 more sources

Systematic errors in the choice of dose level of direct oral anticoagulants: urgency of an issue and approaches to its solution

Медицинский совет, 2021
The article presents updated information on the frequency of use of non-recommended low dosing of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
S. R. Gilyarevskiy, N. G. Bendeliani, M. V. Golshmid, I. M. Kuzmina   +3 more
doaj   +1 more source

Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience

Case Reports in Hematology, 2020
Heparin-induced thrombocytopenia is a life-threatening complication of exposure to heparin. Heparin-induced thrombocytopenia results from an autoantibody directed against platelet factor 4 in complex with heparin.
Mohamed Aon, Omar Al-Shammari
doaj   +1 more source

The laboratory and the direct oral anticoagulants

Blood, 2013
Although direct oral anticoagulants do not need laboratory testing for dose adjustment, there are instances when laboratory measurement of the drug anticoagulant effect may be useful. They include before initiation of treatment, before surgical or invasive procedures, on the occasion of hemorrhagic or thrombotic events, and whenever immediate reversal ...
openaire   +4 more sources

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source